Next Phase Newsletter

A corporate venture fund of a pharmaceutical seeks to invest in technologies that are complementary to the parent company’s R&D activities. The firm seeks to invest $5-7M as initial investment, and can invest up to $20M over the company’s lifecycle. The firm will focus on investing in companies in US and Europe. 
 
The firm focuses on investing in therapeutics, platform technologies, and digital technologies. In therapeutics, the firm has a strong interest in cell/gene therapy, as well as platform technologies including any platforms that can find or develop drugs across multiple therapeutic areas. Within digital technologies, the firm primarily seeks applications that help with target identification and drug design, accelerating drug discovery and development. The firm does not invest in medical devices or diagnostics. In terms of stage of development, the firm focuses on pre-clinical and early clinical stage opportunities. 
 
The firm does not have specific company or management team requirements. The firm does not lead investments and does not require board representation. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A French venture capital firm that has an additional office in the USA is actively seeking investment opportunities within life sciences and healthcare sectors, with a focus on early stage. Initial investments can range from $100K – 3M, and largely varies by deal. The firm typically invests in the form of equity, and may take less equity in exchange for preemptive or pro-rata rights. The firm will consider global opportunities but focuses on USA and Europe-based companies. 

The firm is interested in various opportunities within therapeutics, devices, diagnostics, and digital health. In therapeutics, the firm is excited about platform technologies (especially in oncology), DNA repair, and novel drug delivery mechanisms. Within devices, technologies that integrate or combine new technologies such as robotics, smart devices, IoT, and imaging are areas of interest. In diagnostics, point of care diagnostics technologies that can substantially transform the current standard of care are of interest. Lastly, within digital health, the firm is interested in telehealth, novel digital interventions, and any technology that successfully leverages AI to improve patient outcomes and clinical workflow. The firm is mostly stage and indication agnostic but tend to stray away from cardiovascular and CNS indications. 

The firm has no specific company or management team requirements. The firm seeks to be a very active, hands-on investor and can support their portfolio companies on their operations, scalability, regulatory strategy, and more. The firm has a growing advisory board that companies can seek to leverage. The firm can act as either a lead or co-investor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A premier Saudi investment firm boasts a diverse portfolio that spans multiple asset classes, including real assets and alternative investments. Over the past decade, the investment firm has evolved into one of the region’s most compelling success stories, driven by a steadfast commitment to delivering value, fostering partnerships, and catalyzing sustainable development. Their vision is to become a leading integrated solutions provider in cell and gene therapy in Saudi Arabia, establishing themselves as the first globally trusted partner in precision medicine within the Middle East. The firm focus on providing research, manufacturing, and a comprehensive range of services related to genomic medicine, targeting local, regional, and international markets. Check sizes vary and are flexible but on average range between USD $5-10M. The firm aims to act as a catalyst for developing this vital industry and emphasize the importance of the private sector in supporting emerging, innovative sectors. Their aspiration is to accelerate the delivery of groundbreaking innovations and ensure patient access to treatments for chronic and rare diseases in the region. The firm is committed to contributing to the localization of the biotechnology industry as part of the global system and building national expertise to achieve these ambitious goals. 

Within therapeutics, the firm is focused on cell and gene therapy in IND, Phase 1 and/or moving into Phase 2. There are several indications of interest, including orphan diseases, oncology, neurology, immunology, cardiovascular diseases, and diabetes. For Tech-Driven Biosciences, the firm is interested in AI-driven platforms for drug discovery and clinical development. 

The firm is only interested in companies willing to work with Saudi Arabia toward the goal of bringing biotech innovation to the region through manufacturing and clinical development. A carve out or partnership in the region is necessary. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm that manages just under $100 million in assets across 4 funds makes equity investments into companies ranging from a few hundred thousand dollars to $3 million with additional capital reserved for follow on rounds. The firm is looking for companies located throughout the United States and plans to make 2-3 new investments over the next 9-12 months. The firm will invest in both seed and later stage companies. 

The firm is looking for companies developing Medical Devices and Diagnostics, Healthcare IT products and Life Science Research Tools with an emphasis on fast to market low capital intense products that reduce the cost of delivering quality healthcare. The firm is open to all sub-sectors and indications in the medical technology space except for those targeting diseases and disorders of the spine. 

The firm is looking for companies with skilled and experienced management teams. The firm generally looks to take a board seat into companies after investment and play an active role in the management. The firm is willing to invest in both public and privately held companies. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A VC firm is investing from its fifth fund that was closed in 2023. The firm focuses exclusively on early stage and seed investments in medical device companies. The firm provides seed, first, or second round of financing, typically in equity. The initial investment in a company ranges from $250K to $3M, with follow-on financing rounds. Accordingly, the firm invests between $2-6M over the life of an investment. The firm typically invests in companies that are based in the US, but may consider exceptional opportunities abroad. The firm is actively seeking new investment opportunities. 

The firm is specifically looking for medical devices that address cardiovascular, orthopedic indications. The firm has no clinical requirements and will invest in design stage. The product must be based on strongly protected IP. 

The firm prefers to invest in companies that are not looking to develop their own sales team, but rather developing a technology that can be sold at a healthy premium to a company which already has the requisite sales and marketing teams in place. The firm generally takes a board seat, but is not a requirement. In addition, the firm prefers to assume a role on the company’s scientific advisory board. The firm is looking for companies with a strong and experienced management team. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.